Condition
Macular Degenerative Disease
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Enrolling By Invitation1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03167203Phase 1Enrolling By InvitationPrimary
A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy
NCT06965426Not ApplicableRecruitingPrimary
Effect of Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation on Skin Carotenoid Concentration: A Six-Month, Placebo-Controlled Crossover Study
Showing all 2 trials